Research and Markets (http://www.researchandmarkets.com/research/vw7pvx/pharmapoint)
has announced the addition of the "2014
Report on the US Hepatitis C Virus Market - Forecasts to 2022"
report to their offering.
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV)
that results in acute or chronic presentation. The disease is often
asymptomatic, but infected patients may experience fatigue, joint pain,
itchy skin or jaundice. There is no effective vaccine against HCV, so
the market is driven by therapeutics. Currently, drug combinations
containing pegylated interferon (e.g., Roche's Pegasys and Merck's
PegIntron) and ribavirin (e.g., Roche's Copegus and Merck's Rebetol) are
used to treat HCV infection.
Vertex's Incivek is the current market leader. It was among the first
DAA HCV therapies launched in the US. Incivek's improved efficacy over
the previous standard of care (i.e., peginterferon and ribavirin
combination therapy) in the treatment of the most prevalent HCV genotype
in the US, HCV GT1, enabled the drug to quickly capture the market.
Key Topics Covered:
1 Table of Contents
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Opportunity and Unmet Need
7 Pipeline Assessment
8 Market Outlook
For more information visit http://www.researchandmarkets.com/research/vw7pvx/pharmapoint
[ Back To NFVZone's Homepage ]